Research and Reports in Immunology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1-845-208-9209

Rapid Communication - Research and Reports in Immunology (2022) Volume 5, Issue 2

Immunology, immunopathogenesis and immunotherapeutics of COVID-19: An outline

Farshid Noorbakhsh*

Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding Author:
Farshid Noorbakhsh
Department of Immunology
School of Medicine
Tehran University of Medical Sciences, Tehran, Iran
E-mail: [email protected]

Received: 25-Mar-2022, Manuscript No. AARRI-22-110; Editor assigned: 28-Mar-2022, Pre QC No. AARRI-22-110 (PQ); Reviewed: 11-Apr-2022, QC No. AARRI-22-110; Revised: 18-Apr-2022; AARRI-22-110 (R); Published: 25-Apr-2022, DOI: 10.35841/aarri-5.2.110

Citation: Noorbakhsh F. Immunology, immunopathogenesis and immunotherapeutics of COVID-19: An outline. Res Rep Immunol. 2022;5(2):110

Visit for more related articles at Research and Reports in Immunology

Abstract

Coronavirus illness 2019 (COVID-19) contamination which is caused by serious intense respiratory disorder coronavirus-2 (SARS-CoV-2) has driven to a “public wellbeing crisis of worldwide concern” (PHEIC). The disease is profoundly infectious, contains a tall mortality rate, and its pathophysiology remains ineffectively caught on Aspiratory aggravation with considerable lung harm beside generalized resistant dysregulation are major components of COVID-19 pathogenesis. The previous component, lung harm, appears to be at slightest in portion a result of immune dysregulation. Undoubtedly, considers have revealed that resistant change isn't simply an affiliation, because it might happen in systemic contaminations, but, exceptionally likely, the center pathogenic component of COVID-19.

Keywords

SARS-CoV-2, COVID-19, Immune response, Immunotherapy.

Introduction

In December 2019 the primary cases of pneumonia caused by an obscure irresistible specialist were detailed in Wuhan, China. The irresistible operator was afterward found to be a novel beta coronavirus (β CoV) that was called extreme intense respiratory disorder coronavirus 2 (SARS-CoV-2), due to its phylogenetic similitude with SARS-CoV. Contaminations before long got to be broad in China and the rest of the world driving to the affirmation of a widespread and a “public wellbeing crisis of worldwide concern” (PHEIC) by WHO. The so-called coronavirus infection 2019 (COVID-19) contains a higher seriousness and mortality rate within the elderly, in patients with basic conditions like hypertension and diabetes, and in individuals with lessened safe movement [1]. In expansion to being a major risk to open wellbeing, the widespread has moreover influenced social life and worldwide economy. Various investigate bunches have begun exploring potential antiviral operators as well as the plausibility to create a immunization [1].

Pneumonia related with lung harm is the major clinicopathological appearance of COVID-19. Pneumonia shifts from mellow to serious and obsessive discoveries extend from minor serous exudates to aspiratory edema and diffuse alveolar harm. The last mentioned underlies “acute respiratory trouble syndrome” (ARDS) which is seen in a few patients and might lead to diminished blood O2 immersion and life-threatening hypoxemia [2]. Inclusion of cardiovascular framework within the shape of intense myocardial damage, thromboembolism and ischemic occasions has been detailed. Neurological issues counting brainstem glitch happen in some patients and may well be mindful for respiratory disappointment indeed within the nonappearance of diffuse lung harm. Nephrological and gastrointestinal inclusions have moreover been detailed [3]. COVID-19 organ/tissue harm is related with systemic irritation and the so-called “cytokine discharge syndrome” (CRS). Whereas coronaviruses have the capacity to dispense coordinate harm to epithelial tissues through epithelial cell damage and corruption, prove demonstrates that resistant framework activation/perturbation is the major cause of organ/tissue harm in COVID-19. Ponders on patients with COVID-19 have appeared that the infection triggers the discharge of different fiery arbiters counting fiery cytokines that are mainly delivered by monocytes and macrophages. Considers on CRS caused by SARS-CoV-2 disease have been performed on fringe blood; in any case, it is likely that neighborhood concentrations of cytokines are exceedingly upgraded within the lung tissue where alveolar macrophages are confronted with a incredible number of viral particles [4].

This immunological angle of illness, as well as the pressing ought to create a antibody, requires a more profound downplaying of COVID-19 immunology. Additionally, utilizing cytokines, specific antibodies or healing plasma for illness immunotherapy requests distant better;a much better;a higher;a stronger;an improved">a much better understanding of SARS-CoV-2 resistant framework interactions. In this audit, we have pointed to supply an outline of three distinctive but related perspectives of COVID-19 immunology; resistant reaction to SARS-CoV-2, components of resistant dysregulation and potential procedures to do immunotherapy for the administration of illness [5].

References

  1. Xu Z, Shi L, Wang Y, Zhang J, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med. 2020;8(4):420-22.
  2. Indexed at, Google Scholar, Cross Ref

  3. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-720.
  4. Google Scholar

  5. Huang Y, Wang X, Li L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. The Lancet. 2020; 395:497-06.
  6. Indexed at, Google Scholar, Cross Ref

  7. Kindler E, Thiel V, Weber F, et al. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Adv Virus Res. 2016;96:219-43.
  8. Indexed at, Google Scholar, Cross Ref

  9. Acharya D, Liu G, Gack MU, et al. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20(7):397-98.
  10. Indexed at, Google Scholar, Cross Ref

Get the App